U-M Center for RNA Biomedicine's 9th Annual Symposium | March 6 – 8, 2025 | |
Join us for the Center for RNA Biomedicine's 9th Annual RNA Symposium: From Sequence to Solutions, which also marks the inaugural event co-hosted by our new partner, The Society for RNA Therapeutics. This gathering brings together thought leaders and pioneering researchers in the fields of RNA science and biomedicine.
The premier three-day symposium will feature dynamic presentations, engaging panel discussions, and interactive sessions, all designed to push the boundaries of RNA research and foster interdisciplinary collaboration. Don't miss this opportunity
Click here to view and download the full program..
| |
Don't miss out! The deadline for registration is
THIS Thursday, February 27th.
| |
|
Senior Vice President, Innovation Chemistry,
Scientific Advisory Board Member,
Distinguished Research Scientist
Alnylam Pharmaceuticals
| |
Dr. Muthiah (Mano) Manoharan is a world-leading chemist in the areas of oligonucleotide chemical modifications, conjugation chemistry, and delivery platforms. Dr. Manoharan is currently Senior Vice President of Innovation Chemistry, a Scientific Advisory Board Member, and a Distinguished Research Scientist at Alnylam Pharmaceuticals. He and his team pioneered the discovery and development of the chemical modifications that make RNA interference-(RNAi) based human therapeutics possible. He has authored more than 215 publications and over 400 abstracts and is the inventor of more than 250 issued U.S. patents. Prior to Alnylam, Dr. Manoharan worked at Ionis (formerly Isis) Pharmaceuticals in the field of antisense oligonucleotide therapeutics. Dr. Manoharan has been honored with the 2019 Lifetime Achievement Award of the Oligonucleotide Therapeutics Society. | |
Michelle Hastings, Ph.D., director of RNA Therapeutics at U-M, to speak at Michigan Medicine's Rare Disease Day Symposium | |
This Friday, February 28th—National Rare Disease Day—Michigan Medicine will host a symposium featuring key discussions from researchers and advocates. Highlights include presentations by Dr. Michelle Hastings, Director of RNA Therapeutics, and Dr. Elizabeth Ames, pediatric geneticist at Mott Children's Hospital. Topics will cover the diagnostic odyssey and advancements in rare disease research.
The dialogue continues at next week's Center for RNA Biomedicine's 9th Annual RNA Symposium, where Dr. Ames and Dr. Peter Todd, clinical director of RNA Therapeutics, will co-moderate a patient advocacy panel. This event will explore the intersection of RNA research and patient care.
Both events showcase Michigan Medicine and the Center's commitment to advancing research and advocacy, inviting engagement from researchers, clinicians, and advocates.
Click here for more information on Friday's Rare Disease Symposium at Michigan Medicine.
| |
Meetings
For all details regarding each upcoming meeting, please click the banners below.
| | | | |